Chemomab Therapeutics DRC company info

What does Chemomab Therapeutics DRC do?
Chemomab Therapeutics (NASDAQ:CMMB) is a biotech company focusing on the discovery and development of innovative therapies for fibrosis-related diseases and inflammation. With a deep understanding of the molecular pathways that drive these conditions, Chemomab is committed to advancing a pipeline of novel drug candidates designed to address unmet medical needs. The company's lead project involves a monoclonal antibody targeting a key regulator of fibrosis and inflammation, showing promise in various clinical trials. Chemomab aims to transform the treatment landscape for patients suffering from debilitating diseases where current therapies are inadequate or non-existent, demonstrating a strong commitment to improving patient outcomes through scientific excellence and targeted drug development.
Chemomab Therapeutics DRC company media
Company Snapshot

Is Chemomab Therapeutics DRC a public or private company?

key
Ownership
Public

How many people does Chemomab Therapeutics DRC employ?

people
Employees
19

What sector is Chemomab Therapeutics DRC in?

pie chart
Sector
Health Care

Where is the head office for Chemomab Therapeutics DRC?

location pin
Head Office
Tel Aviv, Israel

What year was Chemomab Therapeutics DRC founded?

founded flag
Year Founded
2011
What does Chemomab Therapeutics DRC specialise in?
/Immunotherapy Development /Clinical Trials /Monoclonal Antibodies /Inflammation Treatments /Fibrosis Therapies /Cancer Research

What are the products and/or services of Chemomab Therapeutics DRC?

Overview of Chemomab Therapeutics DRC offerings
Development of CM-101, a first-in-class monoclonal antibody targeting CCL24 for fibrotic diseases.
Clinical trials for treating Primary Sclerosing Cholangitis, a rare liver disease.
Studies on CM-101's effectiveness for Non-Alcoholic Steatohepatitis, a liver condition.
Research into CM-101's potential for treating systemic sclerosis.
Exploration of CM-101's application in idiopathic pulmonary fibrosis.
Investigation into CM-101's effects on kidney fibrosis.

Who is in the executive team of Chemomab Therapeutics DRC?

Chemomab Therapeutics DRC leadership team
  • Dr. Adi Mor George Ph.D.
    Dr. Adi Mor George Ph.D.
    Co-Founder, Chief Scientific Officer, CEO & Executive Director
  • Ms. Sigal  Fattal CPA, M.B.A.
    Ms. Sigal Fattal CPA, M.B.A.
    Chief Financial Officer
  • Dr. Matthew B. Frankel M.B.A., M.D.
    Dr. Matthew B. Frankel M.B.A., M.D.
    Chief Medical Officer & VP of Drug Development
  • Barbara  Lindheim
    Barbara Lindheim
    Consulting Vice President of Investor & Public Relations, Strategic Communications